Stocktoria
AbCellera Biologics Inc. ABCL
AbCellera Biologics Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M | $233.2M |
| R&D expense | $186.8M | $167.3M | $175.7M | $107.9M | $62.1M | $29.4M |
| Operating income | -$217.1M | -$314.8M | -$237.2M | $216.5M | $204.4M | $156.0M |
| Income tax | -$31.2M | -$37.5M | -$27.6M | $80.6M | $65.7M | $38.9M |
| Net income | -$146.4M | -$162.9M | -$146.4M | $158.5M | $153.5M | $118.9M |
| EPS (diluted) | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 | $0.45 |
| Operating cash flow | -$131.3M | -$108.6M | -$43.9M | $277.4M | $244.6M | $22.7M |
| Free cash flow | -$174.1M | -$187.0M | -$120.8M | $206.7M | $186.1M | $13.0M |
| Cash & equivalents | $61.8M | $55.6M | $52.2M | $44.9M | $8.2M | $900,000 |
| Inventory | $6.3M | $0 | — | — | — | — |
| Total assets | $1.4B | $1.4B | $1.5B | $1.5B | $1.3B | $1.0B |
| Total liabilities | $390.0M | $304.5M | $335.8M | $307.6M | $292.8M | $175.0M |
| Shareholders' equity | $966.9M | $1.1B | $1.2B | $1.2B | $1.0B | $830.5M |
Growth · year-over-year · Revenue CAGR -20.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +160.6% | -24.2% | -92.2% | +29.4% | +60.9% | — |
| Net income growth | — | — | -192.4% | +3.3% | +29.1% | — |
| EPS growth | — | — | -202.0% | +4.2% | +6.7% | — |
| Free cash flow growth | — | — | -158.5% | +11.1% | +1329.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.